Immune infiltration-associated serum amyloid A1 predicts favorable prognosis for hepatocellular carcinoma

Figure 1 Serum amyloid A1 expression in hepatocellular carcinoma tumor and surrounding non-tumor or genotype-tissue expression liver tissues and its effect on the survival rate of hepatocellular carcinoma patients. A: A total of 160 hepatocellular carcinoma (HCC) tumor samples and 369 normal liver tissues were included to evaluate the serum amyloid A1 (SAA1) transcript expression level. Normal liver tissues are comprised of surrounding non-tumor and genotype-tissue expression liver tissues; B: HCC patients were divided into two groups based on the SAA1 expression level, and conducted the overall survival (OS); C: Progression-free survival (PFS); D: Recurrence-free survival analysis (RFS). The log-rank P value was subjected to evaluate the statistical difference.